TGFB1 and liver dysplastic nodule: We conclude that antagonizing A2BAR may be an effective strategy to alleviate diabetic glomerulopathy by directly modulating TGF-β pathogenic signaling in podocytes and potentially improving glomerular function through the attenuation of phenotypic dedifferentiation and the associated inflammatory cascade in DN.